This real-world study evaluated a short-course, season-oriented Stapokibart (anti-IL-4Rα monoclonal antibody) treatment strategy for moderate-to-severe seasonal allergic rhinitis (SAR) in patients from Northern China, timed to the local allergy season.
The season-aligned, short-course Stapokibart regimen demonstrated clinical effectiveness for moderate-to-severe SAR in a real-world Northern China population, though specific outcome numbers are not available from the provided abstract.
Real-world design limits causal inference; findings may not generalize beyond Northern China's specific pollen seasons; no comparator arm reported.
A short-course, season-timed Stapokibart strategy may be a practical option for moderate-to-severe SAR patients in regions with defined pollen seasons. Clinicians should consider local seasonal patterns when scheduling biologic therapy for SAR.
Explore related topics
